1,012 results on '"niraparib"'
Search Results
2. Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (NADIR)
3. A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
4. Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
5. Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
6. Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10)
7. A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
8. Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
9. Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
10. Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
11. A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
12. A Study of Niraparib in Patients with Ovarian Cancer in Clinical Practice
13. A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
14. A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer with DNA Repair Defects
15. A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS)
16. Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
17. A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
18. Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE)
19. Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)
20. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
21. A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)
22. A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)
23. Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
24. Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study. (NIRAPARIB)
25. Niraparib in Patients With Pancreatic Cancer
26. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)
27. Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
28. SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO)
29. Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer (NIRVANA-1)
30. Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
31. PARP Inhibition for Gliomas (PI-4G or π4g) (OU-SCC-PI-4G)
32. ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
33. A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (QUEST)
34. A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
35. Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
36. Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
37. Niraparib in the Treatment of Patients with Advanced PALB2 Mutated Tumors (PAVO)
38. Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)
39. Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)
40. Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA)
41. Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
42. Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR)
43. A Phase I Study of Niraparib Administered Concurrently with Postoperative RT in Triple Negative Breast Cancer Patients (UNITY)
44. A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
45. Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)
46. 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)
47. A Study of Niraparib in Combination with Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) (NICHOL)
48. Niraparib As First Line Therapy with Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC)
49. Niraparib + Dostarlimab in BRCA Mutated Breast Cancer
50. Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.